Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report) is expected to be announcing its H1 2026 results before the market opens on Thursday, August 20th. Analysts expect the company to post earnings of $0.0447 per share and revenue of $479.6290 million for the quarter. Parties can find conference call details on the company’s upcoming H1 2026 earning report for the latest details on the call scheduled for Wednesday, August 19, 2026 at 7:00 PM ET.
Telix Pharmaceuticals Stock Up 1.3%
Shares of NASDAQ TLX opened at $11.88 on Wednesday. Telix Pharmaceuticals has a fifty-two week low of $6.28 and a fifty-two week high of $12.60. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The company’s 50 day simple moving average is $10.82 and its 200 day simple moving average is $9.57.
Analyst Upgrades and Downgrades
A number of analysts have commented on the stock. Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Citigroup cut their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Royal Bank Of Canada cut Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.40.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers raised its holdings in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd bought a new stake in shares of Telix Pharmaceuticals in the 4th quarter valued at $89,000. IHT Wealth Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 2nd quarter valued at $213,000. OLD Mission Capital LLC acquired a new stake in Telix Pharmaceuticals during the 4th quarter worth $111,000. Finally, JPMorgan Chase & Co. acquired a new stake in Telix Pharmaceuticals during the 3rd quarter worth $243,000.
About Telix Pharmaceuticals
Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.
The company’s pipeline spans both imaging and therapeutic candidates.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
